Relmada Therapeutics Inc Total Liabilities
Relmada Therapeutics Inc total liabilities. Based on the latest financial reports, Relmada Therapeutics Inc (RLMD) has total liabilities worth $16.63 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Relmada Therapeutics Inc (RLMD) liquidity interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Relmada Therapeutics Inc (2012–2025)
Total liabilities of Relmada Therapeutics Inc from 2012 to 2025. This chart illustrates how Relmada Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Relmada Therapeutics Inc (RLMD) asset resilience to evaluate the company's liquid asset resilience ratio.
Relmada Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Relmada Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Avidbank Holdings, Inc. Common stock
NASDAQ:AVBH
|
USA | $2.36 Billion |
|
Southern States Bancshares Inc
NASDAQ:SSBK
|
USA | $2.56 Billion |
|
Guangdong PAK Corporation Co Ltd
SHE:300625
|
China | CN¥896.13 Million |
|
Jiangsu Flag Chemical Industry Co Ltd
SHE:300575
|
China | CN¥2.81 Billion |
|
Focus Hotmelt Co. Ltd. A
SHE:301283
|
China | CN¥914.00 Million |
|
Tarczynski S.A.
WAR:TAR
|
Poland | zł1.47 Billion |
|
Beijing AriTime Intelligent Control Co Ltd
SHG:600560
|
China | CN¥1.43 Billion |
|
Dongguan Chitwing Technology Co Ltd
SHE:002855
|
China | CN¥1.38 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Relmada Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Relmada Therapeutics Inc.
Liquidity & Leverage Metrics
Relmada Therapeutics Inc Total Liabilities Ratios Explained
Relmada Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Relmada Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Relmada Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Relmada Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.49 Million | -27.24% |
| 2024-12-31 | $10.30 Million | -15.57% |
| 2023-12-31 | $12.19 Million | -2.20% |
| 2022-12-31 | $12.47 Million | -17.21% |
| 2021-12-31 | $15.06 Million | +19.50% |
| 2020-12-31 | $12.60 Million | +764.53% |
| 2019-12-31 | $1.46 Million | -82.97% |
| 2018-12-31 | $8.56 Million | +521.89% |
| 2017-12-31 | $1.38 Million | -57.00% |
| 2016-12-31 | $3.20 Million | -79.45% |
| 2015-12-31 | $15.58 Million | 0.00% |
| 2014-12-31 | $15.58 Million | -42.01% |
| 2014-06-30 | $26.87 Million | 0.00% |
| 2013-12-31 | $26.87 Million | +384025.37% |
| 2012-12-31 | $7.00K | -- |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more